Amneal launches generic fluorometholone ophthalmic suspension

Amneal is introducing fluorometholone ophthalmic suspension, 0.1%. The product received 180-day competitive generic therapy exclusivity from the Food and Drug Administration.

FML suspension is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.

[Read more: Amneal, Strides to intro generic Vascepa]

“We are starting the new year with the launch of another complex high-value product, which will help drive our continued growth,” said Andy Boyer, executive vice president, chief commercial officer, generics, at Amneal. “Ophthalmic products represent a less crowded and more durable category, and we continue to expand our portfolio of affordable medicines.”

[Read more: Amneal debuts 2 generics]

FML had a market value of roughly $62 million, for the 12 months ended November 2023, per IQVIA.